This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study design
This was a prospective cohort study that was carried out at 83 centres. The length of follow-up was 72 hours or until completion of therapy, whichever came first. Loss to follow-up was not reported. Hospital staff collected the data and submitted them to an external evaluation group for analysis. No blinding was performed.
Analysis of effectiveness
All patients included in the initial study sample appear to have been considered in the analysis of effectiveness. The primary outcome measure was the rate of PIV restarts. Other clinical end points were the rates of phlebitis and of total catheter-related complications. The baseline comparability of the study groups was not discussed.
Effectiveness results
There were 4,123 PIV restarts in the tape group and 717 in the stabilisation device group. Thus, the rate of PIV restarts was 70.7% in the tape group and 16.6% in the stabilisation device group, which corresponds to a reduction of approximately 76% with the stabilisation device. The median difference between the two average restart rates was 0.5542 (confidence interval, CI: 0.5154 to 0.5929; p=0.0001).
The rate of phlebitis was 3.6% in the tape group and 0.7% in the stabilisation device group, which corresponds to a reduction of approximately 80% with the stabilisation device. The relative risk of phlebitis with the tape was 5.0824 times greater than with the stabilisation device (CI: 0.6172 to 7.1411; p<0.001).
The rate of total complications was 47.6% in the tape group and 16.0% in the stabilisation device group, which corresponds to a 67% decrease with the stabilisation device. The relative risk of total complications with the tape was 4.7713 times greater than with the stabilisation device (CI: 4.3832 to 5.1939; p<0.001).
Clinical conclusions
The effectiveness analysis showed that the stabilisation device significantly reduced the need for PIV restarts and catheter-related complications (including phlebitis) in comparison with conventional tape.
Measure of benefits used in the economic analysis
The health outcomes were left disaggregated and no summary benefit measure was used in the economic analysis. In effect, a cost-consequences analysis was carried out.
Direct costs
The perspective of the analysis was not explicitly stated, but only hospital costs were included in the study. The items considered were material costs (catheter, extension set with needleless cap, blunt cannula, saline flush, gauze, gloves, and alcohol preparation pad), complications costs (phlebitis and other catheter-related complications) and personnel costs (nurse time). The unit costs were presented separately from the quantities of resources used. The source of the costs was not explicitly reported. Resource consumption referred to a hypothetical patient and was not related to the actual consumption observed in the sample of patients included in the effectiveness analysis. The annual costs referred to a 300-bed hospital with 60,000 annual PIV catheter placements. Discounting was not relevant due to the short timeframe of the analysis. The price year was not reported.
Statistical analysis of costs
The costs were treated deterministically.
Indirect Costs
The indirect costs were not included.
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Sensitivity analysis
No sensitivity analysis was carried out.
Estimated benefits used in the economic analysis
See the 'Effectiveness Results' section.
Cost results
The total annual costs of starting a PIV catheter were $264,705.88 in the tape group and $360,000.00 in the stabilisation device group.
The annual costs of unscheduled restarts were $185,294.12 in the tape group and $72,000.00 in the stabilisation device group.
Therefore, the total annual material costs were $450,000.00 in the tape group and $432,000.00 in the stabilisation device group, a difference of $18,000 in favour of the stabilisation device.
Further cost-savings could be realised if the cost analysis took labour costs and complication rates into consideration. Thus, in a hypothetical 300-bed hospital with 60,000 annual PIV catheter placements, the total annual cost reduction with a stabilisation device compared with standard tape would be $277,085 ($18,000 for material costs, $22,320 for complication reduction and $236,765 for nurse time savings).
Synthesis of costs and benefits
A synthesis of the costs and benefits was not relevant as a cost-consequences analysis was carried out.
Authors' conclusions
The use of a catheter stabilisation device was an effective, safe, and cost-saving alternative to conventional tape in the USA.
CRD COMMENTARY -Selection of comparators
The choice of the comparator was appropriate as it reflected the conventional approach in the author's setting. You should decide whether tape is a valid comparator in your own setting.
Validity of estimate of measure of effectiveness
The effectiveness analysis was based on a prospective observational study. The use of a randomised trial would have been more appropriate since, as the author pointed out, the results of the analysis could have been affected by selection bias. Further, since the two groups were not evaluated concurrently, factors other than the study intervention could have influenced the nurses' behaviour. The fact that blinding was not performed and nurses were aware of the objective of the study could have affected how meticulously the catheters were changed during the intervention period. In addition, data collection did not include the presence of co-morbidities. Thus, it was unclear whether the two groups of patients were comparable at baseline. The evidence came from several centres so the study sample should have been representative of the patient population. No formal justification for the size of the sample was provided, and power calculations were not reported. However, a large sample of patients was included. Details of the follow-up were unclear. These issues tend to limit the internal validity of the analysis, as the author acknowledged.
